Mark Mcdade

Insider Reports History

Entity
Individual
Location
C/O Protine Design Lab, 7442 North Marcer Way, Mercer Island, WA
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mark Mcdade:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Tourmaline Bio, Inc. Director Common Stock 448K $14.6M $32.50 Jan 29, 2024 By Qiming U.S. Healthcare Fund III,L.P.
Tourmaline Bio, Inc. Director Common Stock 183K $5.95M $32.50 Jan 29, 2024 By Qiming U.S. Healthcare Fund I,L.P.
Tourmaline Bio, Inc. Director Common Stock 110K $3.58M $32.50 Jan 29, 2024 By Qiming U.S. Healthcare Fund II,L.P.
Tourmaline Bio, Inc. Director Common Stock 518 $16.8K $32.50 Jan 29, 2024 Direct
Icosavax, Inc. Former Director Common Stock 0 $0 $15.29 Feb 19, 2024 By Qiming U.S. Healthcare Fund II, L.P.
Icosavax, Inc. Former Director Common Stock 0 $0 $15.29 Feb 19, 2024 Direct
Tourmaline Bio, Inc. Director Stock Option (Right to Buy) 10K Jun 5, 2024 Direct
Icosavax, Inc. Former Director Stock Option (Right to Buy) 0 Feb 19, 2024 Direct

Insider Reports Filed by Mark Mcdade

Symbol Company Period Transactions Value $ Form Type Date Filed Role
TRML Tourmaline Bio, Inc. Jun 5, 2024 1 $0 4 Jun 7, 2024 Director
ICVX Icosavax, Inc. Feb 19, 2024 4 $0 4 Feb 20, 2024 Former Director
TRML Tourmaline Bio, Inc. Jan 29, 2024 1 $3.25M 4 Jan 31, 2024 Director
TALS Tourmaline Bio, Inc. Oct 19, 2023 4 $0 4 Oct 23, 2023 Director
TALS Talaris Therapeutics, Inc. Jun 13, 2023 1 $0 4 Jun 14, 2023 Director
ICVX Icosavax, Inc. Jun 6, 2023 1 $0 4 Jun 8, 2023 Director
ICVX Icosavax, Inc. Jun 10, 2022 2 $0 4 Jun 14, 2022 Director
TALS Talaris Therapeutics, Inc. Jun 9, 2022 1 $0 4 Jun 13, 2022 Director
ICVX Icosavax, Inc. Apr 1, 2022 1 $300K 4 Apr 5, 2022 Director